

CAS FORMULATIONS™ (File label CASFORM)

This file is exclusive to STNext.

Subject Coverage	<ul style="list-style-type: none"> • Agrosience * • Coatings • Consumer goods • Cosmetics* 	<ul style="list-style-type: none"> • Food • Materials • Pharmaceuticals* <p>*Areas of focus</p>
File Type	Formulations, Substances, Bibliographic	
Features	Thesauri None. Alerts (SDIs) Weekly, Biweekly (default), Monthly CAS Registry Number® Identifiers <input checked="" type="checkbox"/> Page Images <input type="checkbox"/> Keep & Share <input checked="" type="checkbox"/> SLART <input checked="" type="checkbox"/> Learning Database <input type="checkbox"/> Structures <input type="checkbox"/>	
Record Content	<ul style="list-style-type: none"> • Bibliographic information and abstracts for patents and journal articles reporting formulations • Information about the ingredients included in formulations, including CAS Registry Numbers • Information about the experimental activity of formulations • Text extracted from drug product inserts reported in the DailyMed database 	
File Size	More than 4.5 million records (01/2022)	
Coverage	<ul style="list-style-type: none"> • Formulations from English language patents in Subject Coverage areas, 1996 – present • Formulations from selected patents originally published in Chinese, French, German, Japanese, and Korean • Formulations from journal articles, 2014 – present • Drug product inserts from the DailyMed database 	
Updates	Several times per week	
Language	English	
Database Producer	Chemical Abstracts Service 2540 Olentangy River Road P.O. Box 3012 Columbus, Ohio 43210-0012 USA Phone: 800-753-4227 (North America) Phone: 614-447-3700 (worldwide) Fax: 614-447-3751 Email: help@cas.org Copyright Holder	

CAS FORMULATIONS

Sources

- Patents
 - Journals
 - Drug Product Inserts
-

User Aids

- Support and training materials are available on the web: www.cas.org
 - Online Helps (HELP DIRECTORY lists all help messages available)
 - STNGUIDE
-

Clusters

None

**Related
Databases**

- CAplus
 - CAS Registry
-

Search and Display Field Codes

Fields that allow left truncation are indicated by an asterisk (*). The minimum stem length for left truncation is four (4) characters.

General Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * - Contains single words from Title (TI), Abstract (AB), Chemical Name (CN), Component Name (CNM), Formulation Description (FD), Notes fields (Component Note (CNO), Group Note (GNO), Experimental Activity Note (EAN), Product Activity Note (NOTE) and Process Note (NOTE)), and Vocabulary fields (Group (GVO), Component (CVO), Product (PVO), Target (TVO) and Solvent (SVO)). Also includes CAS Registry Numbers. (Left truncation allowed for all text fields in the Basic Index other than Chemical Name and Vocabulary fields.)	None (or /BI)	S HERBICIDE S FLUOROCARBON? S THICKENER(W)SOLUTIONS S TOPICAL ANESTHETIC/BI S 1071-83-6	AB, ANTE, CCN,GCN, CNM, CNO, CVO, EAN, FD, GNO, GVO, PNTE, PVO, SVO, RN, TI, TVO
Abstract *	/AB	S (WATER(1W)OIL)/AB S HIGH TEMP?/AB S (HIV(W)TREAT?)/AB	AB
Accession Number	/AN	S 2019:51550/AN	AN
Attribution (1)	/ATTR	S DAILYMED/ATTR	ATTR
Author (Inventor) (2)	/AU (or /IN)	S SILBIGER SCOTT M/AU S ANON/AU S O NEILL V?/AU	AU, IN
Component Form Description	/CFR	S POWDER/CFR	CFR
Component Function Description	/CFU	S ENDOTHELIN RECEPTOR A INHIBITORS/CFU	COMPONENT,CFU
Component Markush Description	/CMD	S MARKUSH/CMD	CMD
Component Count (3)	/CMPC	S 1/CMPC	BIB
Component Registry Number	/CMPRN	S 9004-65-3/CMPRN	RN, CMPRN
Chemical Name	/CN	S PROPYLENE GLYCOL/CN	CCN, GCN
Component Name(s) (4)	/CNM	S SORBITOL/CNM S STEAMIC QOS?/CNM	CNM
Component Note*	/CNO	S OLIVE VINEGAR/CNO	COMPONENT
Chemical Name Segment*	/CNS	S METHYLACETALDEHYDE/CNS	CCN, GCN
Component Optionality	/COP	S MANDATORY/COP	COP
CAplus Accession Number	/CPAN	S 2019:656160/CPAN	CPAN
Component Vocabulary	/CVO	S METHYLGLYCOSIDES/CVO	COMPONENT,CVO
Document Number(CA Abstract Number)	/DN	S 169:80023/DN	DN
Delivery Route	/DR	S INTRAOCULARLY/DR	PRODUCT
Document Type	/DT	S INSERT/DT S JOURNAL/DT S PATENT/DT	BIB
Experimental Activity Description	/EAD	S HALF-LIFE/EAD	PRODUCT
Experimental Activity Note*	/EAN	S FUNGICIDE/EAN	PRODUCT
Entry Date (3)	/ED	S 20191003/ED	ED
Field Availability	/FA	S CN/FA S TI/FA	---

CAS FORMULATIONS

Search Field Name	Search Code	Search Examples	Display Codes
Formulation Description*	/FD	S FERTILIZE?/FD	FD
Feature	/FEA	S POWDER?/FEA	FEA
Formulation Number	/FN	S 1000/FN	FN
Group Description	/GDS	S MONOMER/GDS	GDS
Group Form Description	/GFR	S ABRASIVE PARTICLES/GFR	GROUP
Group Function	/GFU	S ACTIVE AGENT/GFU	GROUP
Group Markush Description	/GMD	S MARKUSH/GMD	CHEM
Group Note*	/GNO	S ETHYL/GNO	GROUP
Group Optionality	/GOP	S MANDATORY/GOP S EXCLUDE/GOP	GROUP
Group Registry Number	/GRPRN	S 50-21-5/GRPRN	RN, GRPRN
Group Vocabulary	/GVO	S AVENA SATIVA/GVO	PRODUCT
Group Count (3)	/GRPC	S 4/GRPC	BIB
Inventor (or Author)	/IN (or /AU)	S SILBIGER SCOTT M/AU S ANON/AU S O NEILL V?/AU	IN, AU
Journal Title	/JT	S MUCOSAL IMMUNOLOGY/JT S MUCOSAL IMMUNOL/JT S IP.COM/JT	BIB
Location Section Category	/LCC	S CLAIM/LCC	LOC
Location Section Description	/LCD	S CLAIM?/LCD	LOC
Location Region Page Number	/LCP	S 21/LCP	LOC
National Drug Codes	/NDC	S 10019-115-01/NDC	NDC
Note	/NOTE	S TORREYA/NOTE	NOTE, ANTE, PNTE
Product Final Physical Form	/PF	S OVAL TABLETS/PF	PRODUCT, PF
Product Name Code	/PNC	S GENERIC/PNC	PNC, PRODUCT
Patent Number/Kind Code	/PNK	S CN109498798A/PNK	PN, PI
Product Name Value	/PNV	S GENISTEIN NANOPARTICLES/PNV	PNV, PRODUCT
Product Purpose	/PUP	S ANTI-TUSSIVE/PUP	PRODUCT
Publication Year (3,5)	/PY	S 2018/PY	PY, PI
Product Vocabulary	/PVO	S DRUG DELIVERY SYSTEMS/PVO	PVO, PRODUCT
CAS Registry Number	/RN	S 1071-83-6/RN	RN
Solvent Registry Number	/SOLRN	S 135062-02-1/SOLRN	RN, SOLRN
Solvent Vocabulary	/SVO	S BENZOLINE/SVO	SVO, PRODUCT
Target Description	/TGD	S "COUGH AND COLD"/TGD	PRODUCT
Target Relationship	/TGR	S PREVENTS/TGR	PRODUCT
Target Type	/TGT	S HALLUCINATIONS/TGT	PRODUCT
Target Count (3)	/TGTC	S 1/TGTC	PRODUCT
Title*	/TI	S INFLUENZA/TI	TI, BIB
Target Vocabulary	/TVO	S KABUKI SYNDROME/TVO	TVO, PRODUCT
Update (3)	/UP	S 20200121/UP	UP, BIB

- (1) Drug product inserts only.
- (2) AU and IN are aliases. To restrict authors to journals, add J/DT to your search. To restrict to patents, add P/DT.
- (3) Numeric search field that may be searched with numeric operators or ranges.
- (4) Certain product names are represented in CAS FORMULATIONS with registered trademark symbols, trademark symbols, etc. For those items, use truncation while searching to account for the symbol (e.g., S STEAMIC QOS?/CNM)
- (5) No PY information exists for drug product inserts.

Patent Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Application Date (1)	/AD	S 20190101/AD	AD, PI
Application Number	/AP	S US2018-16229471/AP	AP, PI
Application Year (1)	/AY	S 2018/AY	AY, PI
Inventor (2)	/IN or /AU	S SILBIGER SCOTT M/IN	IN (or AU)
Patent Assignee	/PA	S ALNYLAM/PA	PA
Patent Country	/PC	S US/PC	PN, PI
Patent Number	/PN	S WO2019001567/PN	PN, PI
Patent Number/Kind Code	/PNK	S US 20190083220A1/PNK	PNK, PI
Patent Date (1)	/PD	S 20200121PD	PD,PI

(1) Numeric search field that may be searched with numeric operators or ranges.

(2) AU and IN are aliases in CAS FORMULATIONS

Super Search Fields

Enter a super search code to execute a search in one or more fields that may contain the desired information. EXPAND may not be used with super search fields. Use EXPAND with the individual field codes instead.

Super Search Field Name	Search Code	Fields Searched	Search Examples	Display Codes
Component Information Group Information Group/Component Registry Number(1)	/COMP /GRP /GRN	CFU, CNM, CNO, CVO GFU, GDS, GVO GRPRN, CMPRN	S SUCROSE/COMP S OVALBUMIN/GRP S 1071-83-6/GRN S 104206-82-8/GRN (L) 111991-09-4/GRN	COMP GRP RN
Chemical Name Registry Number	/CN /RN	CCN, GCN GRPRN, CMPRN, SOLRN	S GLIALKA/CN S 1071-83-6/RN	CCN or GCN RN, GRPRN, CMPRN, SOLRN

(1) Searches for Group Registry Numbers and Component Registry Numbers within the same Group.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI AU; D L1 1-5 TI,AU. The fields are displayed or printed in the order requested.

Hit-term highlighting is available in most fields. In the table-like display of the PI (Patent Information) field, highlighting is shown by an arrow on the right side pointing to the line that includes the hit terms.

Format	Content	Examples
AB	Abstract Text	D TI AB
AD	Application Date	D AD or D PI
AMT	Dose Amount	D CHPR D PRODUCT
AP	Application Number	D AP or D PI
AN	Accession Number (Formulation)	D 1-5 AN
ANTE	Activity Note	D ANTE or D PRODUCT
ATTR (1)	Attribution	D ATTR
AU (IN)	Author (or Inventor) Name	D AU or D IN
AY (2)	Application Year	D AY or D PI
CAM	Component Amount	D CHEM

CAS FORMULATIONS

CFR	Component Form Description (CTSV, CFP, CFD)	D CFR
CFU	Component Function Description	D CFU
CMPS	Component Count	D BIB
CN	Chemical Name	D CCN GCN
CNM	Component Name	D CNM
CNO	Component Note	D CHEM D CHPR
CNU	Component Number	D CHEM D CHPR D COMPONENT
CPAN (3)	CAplus Accession Number	D CPAN
CMPRN	Component Registry Number	D CMPRN
CVO	Component Vocabulary	D CVO
DN(3)	Document Number (CA Abstract Number)	D DN
DOS	Dosage Description	D PRODUCT
DT	Document Type	D DT
EAD	Experimental Activity Description	D PRODUCT
EAM	Experimental Activity Measurement	D PRODUCT
EAN	Experimental Activity Note	D PRODUCT
ED	Entry Date	D ED
FD	Formulation Description	D FD
FN	Formulation Number	D FN
GAM	Group Amount	D CHEM
GCN	Group Chemical Name	D GCN
GDS	Group Description	D GDS
GFR	Group Form Description (GTSV, GFP, GFD)	D GROUP
GFU	Group Function Description	D GFU
GLO	Group Location	D CHEM D CHPR D GROUP
GNO	Group Note	D CHEM D CHPR
GNU	Group Number	D CHEM D CHPR D GROUP
GRPRN	Group Registry Number	D GRPRN
GRPS	Group List	D GRPS
GVO	Group Vocabulary	D GVO
JT	Journal Title	D JT
JTA	Abbreviated Journal Title	D JT
LCC	Location Section Category	D LCC
LCD	Location Section Description	D LCD
LCP	Location Region Page Number	D LCP
LOC	Location (LCC, LCD, LCP)	D LOC
NDC	National Drug Code	D NDC
NOTE	Note	D NOTE D ANTE D PNTE
PA	Patent Assignee	D PA
PF	Product Final Physical Form	D PF
PI	Patent Information Table (PN, PD, AP and AD)	D PI
PNC	Product Name Type Code (e.g., author, brand)	D PNC D PRODUCT
PNTE	Process Note	D PNTE D PRODUCT
PNV	Product Name Value	D PNV D PRODUCT
PVO	Product Vocabulary	D PVO
PNU	Product Number	D CHPR D PRODUCT D TARGET

CAS FORMULATIONS

PY(4)	Publication Year	D PY
RN	CAS Registry Number	D RN D CMPRN D GRPRN D SOLRN
SOLRN	Solvent RN	D SOLRN
SUMM	Group/Component Summary	D SUMM
SVO	Solvent Vocabulary	D SVO
TGT	Target Type	D TGT
TI	Title	D TI
TVO	Target Vocabulary	D TVO
UP	Update	D UP

(1) Drug product inserts only.

(2) **No hit term highlighting.**

(3) **Appears in records sourced from patents and journals only.**

(4) PY information in journals does not display.

Predefined DISPLAY and PRINT Formats

Format	Content	Examples
ALL	AN, CPAN, DN, ED, UP, TI, AU, JT, PA, ATTR, DT, PI, FN, FD, GRPS, GRPC, CMPC, TGTC, AB, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR, GRA, GMD, GLO, CMPS, GOP, GVO, GAM, CNU, CRN, CNM, CVO, CCN, CAM, CFU, CFR, CRA, CMD, CNO, COP, PNC, PNV, PNU, PUP, FEA, PF, DOS, PVO, DR, EAD, EAN, EAM, TGD, TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, NOTE	D ALL
BIB	AN, CPAN, DN, ED, UP, TI, AU, JT, PA, ATTR, DT, PI, FN, FD, GRPS, GRPC, CMPC, TGTC	D BIB
CHEM	AN, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR, GRA, GMD, GLO, CMPS, GAM, GOP, GDS, CNU, RN, CNM, CCN, CAM, CFR, CFU, CNO, CRA, CMD, COP	D CHEM
CHPR	AN, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR, GMD, GLO, CMPS, GOP, GAM, GDS, CN, CNU, RN, CNM, CCN, CAM, CFU, CFR, CMD, CMD, COP, PNM, PNC, PNV, PNU, PUP, FEA, PF, DOS, DR, PVO, EAD, EAN, EAM, TGD, TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, NOTE	D CHPR
COMPONENT	AN, CNU, RN, CNM, CCN, CFU, CFR, CAM, CMD, CNO, COP	D COMPONENT
GROUP	AN, GNU, CMPS, RN, GFU, GOP, GAM, GDS, GCN, GNO, GFR, GMD, GLO	D GROUP
LCHEM	AN, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR, GMD, GLO, CMPS, GOP, GVO, GAM, GDS, CN, CNU, RN, CNM, CVO, CCN, CAM, CFR, CNO, CFU, CMD, COP	D LCHEM
PRODUCT	AN, PNM, PNC, PNV, PNU, PUP, FEA, PF, DOS, PVO, DR, EAD, EAN, EAM, TGD, TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, PNTE	D PRODUCT
SOLVENT	AN, PNU, PUP, DR, PF, FEA, RN, CN	D SOLVENT

CAS FORMULATIONS

TARGET	AN, PNU, PUP, FEA, PF, DR, TGD, TGT, TGR	D TARGET
--------	--	----------

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y	N
Patent Application Date	AD	Y	Y
Accession Number	AN	Y	N
Product Activity Note	ANTE	Y	N
Application Patent Number	AP	Y	N
Author Name/ Inventor Name	AU (or IN)	Y	Y
Patent Application Year	AY	Y	Y
Component Form Description	CFR	Y	N
Component Name	CNM	Y	N
CPlus Accession Number	CPAN	Y	Y
Component Registry Number	CMPRN	Y	N
Component Vocabulary	CVO	Y	N
Document Number (CA Abstract Number)	DN	Y	N
Document Type	DT	Y	Y
Entry Date	ED	Y	Y
Formulation Description	FD	Y	Y
Formulation Number	FN	Y	Y
Group Registry Number	GRPRN	Y	N
Group Vocabulary	GVO	Y	N
Inventor Name/Author Name	IN (or AU)	Y	Y
Journal Title	JT	Y	Y
Journal Title	JTA	Y	Y
Patent Assignee	PA	Y	N
Patent Publication Date	PD	Y	Y
Patent Number	PN	Y	N
Product Name Type Code	PNC	Y	Y
Process Notes	PNTE	Y	N
Product Name Value	PNV	Y	Y
Publication Year	PY	Y	Y
Registry Number	RN	Y	N
Solvent Vocabulary	SVO	Y	N
Title	TI	Y	Y
Target Vocabulary	TVO	Y	N

Sample Record 1

=> d all

L1 ANSWER 1 OF 8 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:330339 CASFORMULTNS
 CPAN 2018:518948
 DN 168:320861
 ED 22 Sep 2019
 UP 13 Nov 2019
 TI Ocular film dosage form comprising cyclosporine
 AU Kim, Sang Wook; Kim, Jeong Tae; Yi, Hong Gi
 JT PCT Int. Appl.
 PA Corepharm Bio Co., Ltd.
 DT Patent

PI	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
	WO 2018052185	A1	20180322	WO 2017-KR7426	20170712

FN Form 2
 FD Cyclosporine Eye Film Formulation: Drug Delivery Systems or Ophthalmic Agent
 GRPS G1-G3
 GRPC 3
 CMPC 3
 TGTC 1

AB Disclosed is a unit dosage form comprising cyclosporine and being characterized in that the unit dosage form comprises the same amt. as one dose of cyclosporine, that the cyclosporine is dissolved and present in the state of a solid soln., and that the unit dosage form is a film for application to the eye.

LCC Example
 LCD example 1, Table 1, 3, 4, 5, test example 1, 2, 3, 4, 5

GROUP G1
 GDS Additional ingredients
 CMPS C1
 GOP Mandatory

COMPONENT C1
 RN 59865-13-3
 CNM cyclosporin A
 CVO Formulation active agents; Active agents; Formulation active agent; Formulation active ingredients; Formulation active ingredient; Active ingredients; Active agent; Active ingredient
 CCN Cyclosporin A (9CI, ACI)
 CCN 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane, cyclic peptide deriv. (ZCI)
 CCN 1: PN: US6686454 SEQID: 1 claimed protein; 7: PN: WO2000002548 PAGE: 30 claimed protein; Abrammune; Antibiotic S 7481F1; Arpimune ME; CICPORAL; Cicloral; Cicloral (antibiotic); Ciclosporin; Ciclosporina Germed; Cipol N; Ciqorin; Consupren; CyclASol; Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminoctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-

CAS FORMULATIONS

leucyl-L-valyl-N-methyl-L-leucyl]; Cyclokat; Cyclosporin; Cyclosporine; Cyclosporine A; Cypol-N; Debio088; Equoral; Gengraf; Imusporin; NSC 290193; Neoplanta; Neoral; OL 27-400; Optimmune; Papilock Mini; Ramihyphin A; Restasis; S-Neoral; SDZ-OXL 400; Sandimmun; Sandimmun Neoral; Sandimmun Optoral; Sandimmune; Sandimmune Neoral; Sang-35; SangCyA; Sigmasporin Microoral; Zinograf ME

CAM 0.015 mg
CFU active agent
COP Mandatory

GROUP G2
GDS Additional ingredients
CMPS C2
GOP Mandatory

COMPONENT C2
RN 9002-89-5
CNM polyvinyl alcohol
CVO Film-forming agents; Film formers; Film-forming additives; Film forming agent; Film former
CCN Ethenol, homopolymer (9CI, ACI)
CCN Vinyl alcohol, polymers (8CI)
CCN 100-27H; 100-37H; 100-40H; 1799S; 1R2110; 9P75R; 9X75RS; 9X75SR; A 10 Coex Test 14; A-T; A-T (vinyl polymer); AH 17; AH 22; AH 24; AH 26; AL 06; AL 6; AL 6 (polymer); AQ 2117; AR; AR (vinyl polymer); AVB 8041W; AW 401; AX 20; AX 300SN; AX 400TNG; AZF 8035; Acroflex 1; Acroflex 2; Aibon AU 7002FL; Airvol 103; Airvol 107; Airvol 107SF; Airvol 125; Airvol 125SF; Airvol 165; Airvol 165SF; Airvol 166; Airvol 21-205; Airvol 21-25; Airvol 24-203; Airvol 321LA; Airvol 325; Airvol 325SF; Airvol 350; Airvol 350SF; Airvol 425; Airvol 502
CAM 0.69 mg
CFU film forming agent
COP Mandatory

GROUP G3
GDS Additional ingredients
CMPS C3
GOP Mandatory

COMPONENT C3
RN 57-55-6
CNM Propylene glycol
CVO Plasticizers; Plasticization agents; Softening agents, plasticizers; Flexibilizers; Plasticizer; Plastics, plasticizers for; Plasticizing agents; Softening agent (polymer); Plasticiser; Plasticisers; Polymer softening agents; Plasticizing agent; Plasticizing materials; Plastifying agent; Flexibilizer; Plastic softening agent; Polymer softening agent; Plastifying agents; Plasticizing material; Plasticization agent; Plasticizers agents; Plasticizer agents; Polymer plasticizing agents; Polymer plasticizing agent; Polymer plasticizer; Structure plasticizing agent; Structure plasticizing agents
CCN 1,2-Propanediol (8CI, 9CI, ACI)
CCN (RS)-1,2-Propanediol; (\pm)-1,2-Propanediol; (\pm)-Propylene glycol; 1,2-(RS)-Propanediol; 1,2-Dihydroxypropane; 1,2-Propylene glycol; 1000PG; 2,3-Propanediol; 2-Hydroxypropanol; Adeka PG; Adeka Propylene Glycol PG-P; BS 12; DC 403; Dowfrost; HCH 195; Isopropylene glycol; Kilfrost ABC K Plus; Kilfrost ABC-S; Kilfrost DF K Plus; Kollisol PG; Methylethyl glycol; Methylethylene glycol; Monopropylene glycol; NSC 69860; Nybrine NFP; PG 12; PG-T; PG-T (glycol); ProGlyc 55; Propylene glycol; Propyless;

CAS FORMULATIONS

Radianol 4713; Safewing MP-I 1938; Safewing MP-IV 2001; Sirlene; Solar Winter Ban; Solargard P; Susterra PDO; Ucar 35; α -Propylene glycol; dl-Propylene glycol; DL-1,2-Propanediol

CAM 0.075 mL
 CFU plasticizer
 COP Mandatory
 PNC author
 PNV cyclosporine eye film formulation

PRODUCT PA1

PUP ophthalmic agent
 PF Desc: film
 PVO Films; Thin films; Two-dimensional films; Film; Thin film; Dry film; Dry films; Two-dimensional film; Protective film; Protective films; Protection film; Ophthalmic agents; Ophthalmic drug; Ophthalmic drugs; Ophthalmic agent; Eye drugs; Eye drug; Eye treatment drug; Eye treatment drugs; Optic drug; Optic drugs; Ophthalmic compositions; Ophthalmic composition
 DR ophthalmic

EAD ophthalmological activity
 EAN the effect of the film on healthy rabbit eye was evaluated after 24 hours of administration.
 EAM Non-Numeric: Observed that there was no visible corneal opacity during the observation period before and 24 hours after the administration, and there was no visible erythema or edema in the conjunctival region., Desc: ophthalmological activity

EAD ophthalmological activity
 EAN the effect of the film on 10 corneas of a healthy adult, and sensory evaluation of burning sensation was performed.
 EAM Non-Numeric: there is no feeling of burning at all., Desc: ophthalmological activity

EAD disintegration rate
 EAN the disintegration rate of the film was evaluated by dissolving film in artificial tears.
 EAM Single: 9 seconds, Desc: disintegration rate

EAD thickness
 EAM Single: 0.010 mm, Desc: thickness

EAD weight
 EAM Single: 0.72 mg, Plus/Minus: 0.057 mg, Desc: weight

EAD tensile strength
 EAM Single: 26.37 N/mm², Plus/Minus: 1.34 N/mm², Desc: tensile strength

EAD Elongation
 EAM Single: 165.21 %, Plus/Minus: 3.93 %, Desc: Elongation

EAD cyclosporine dissolution state
 EAN the cyclosporine dissolution state in a film was evaluated.
 EAM Non-Numeric: No microscopic traces of drug particles were observed on the surface of the film under the optical microscope and field emission scanning electron microscope., Desc: cyclosporine dissolution state

PRODUCT PA2

PUP drug delivery systems
 PVO Drug delivery systems; Drug delivery system; Pharmaceutical delivery systems; Delivery systems; DDS; Pharmaceutical composition; Therapeutic

CAS FORMULATIONS

compound delivery system; Drug delivery device; Drug delivery;
 Pharmaceutical compn.; Pharmaceutical compositions; Drug delivery devices;
 Therapeutic compound delivery systems

TGR delivers

TGT drug

TVO Drugs; Medicaments; Pharmaceutical; Drug; Medicines; Prophylactic agents;
 Therapeutic agents; Chemotherapeutic agents; Pharmacological agents;
 Chemotherapeutics; Chemotherapy drugs; Medicament; Pharmacological agent;
 Prophylactic agent; Therapeutic agent; Chemotherapeutic agent

PNTE cyclosporin A is dissolved or dispersed in a solution composed of
 polyvinyl alcohol, a solvent and a plasticizer using a magnetic stirrer.
 the solution was then degassed using an ultrasonic disperser (sonicator)
 and the solution was cast on a suitable substrate to produce a film. the
 resulting film was cut to a size of 0.5 x 0.5 cm and the final product was
 obtained.

Sample Record 2

=> d bib

L1 ANSWER 1 OF 8 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:330339 CASFORMULTNS

CPAN 2018:518948

DN 168:320861

ED 22 Sep 2019

UP 13 Nov 2019

TI Ocular film dosage form comprising cyclosporine

AU Kim, Sang Wook; Kim, Jeong Tae; Yi, Hong Gi

JT PCT Int. Appl.

PA Corepharm Bio Co., Ltd.

DT Patent

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
----- WO 2018052185	---- A1	----- 20180322	----- WO 2017-KR7426	----- 20170712

FN Form 2

FD Cyclosporine Eye Film Formulation: Drug Delivery Systems or Ophthalmic
 Agent

GRPS G1-G3

GRPC 3

CMPC 3

TGTC 1

Sample Record 3

=> d chem

L1 ANSWER 1 OF 8 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:330339 CASFORMULTNS

LCC Example

LCD example 1, Table 1, 3, 4, 5, test example 1, 2, 3, 4, 5

GROUP G1

GDS Additional ingredients

CMPS C1

GOP Mandatory

COMPONENT C1

RN 59865-13-3

CNM cyclosporin A

CCN Cyclosporin A (9CI, ACI)

CAM 0.015 mg

CFU active agent

COP Mandatory

GROUP G2

GDS Additional ingredients

CMPS C2

GOP Mandatory

COMPONENT C2

RN 9002-89-5

CNM polyvinyl alcohol

CCN Ethenol, homopolymer (9CI, ACI)

CAM 0.69 mg

CFU film forming agent

COP Mandatory

GROUP G3

GDS Additional ingredients

CMPS C3

GOP Mandatory

COMPONENT C3

RN 57-55-6

CNM Propylene glycol

CCN 1,2-Propanediol (8CI, 9CI, ACI)

CAM 0.075 mL

CFU plasticizer

COP Mandatory

CAS FORMULATIONS**Sample Record 4**

=> d chpr

L3 ANSWER 1 OF 1 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:281993 CASFORMULTNS

LCC Article

LCD article page 2

GROUP G3

GDS Additional ingredients

CMPS C3

GOP Mandatory

COMPONENT C3

RN 9004-65-3

CNM hydroxypropyl methylcellulose

CCN Cellulose, 2-hydroxypropyl methyl ether (9CI, ACI)

CAM 1 %

CFU active agent

CNO purchased from Aldrich (USA).

COP Mandatory

GROUP G5

GDS P-HEMA-VP polymer

CMPS C1-C2; C4-C5

GOP Mandatory

COMPONENT C1

RN 97-90-5

CNM ethylene glycol dimethacrylate

CCN 2-Propenoic acid, 2-methyl-, 1,1'-(1,2-ethanediyl) ester (ACI)

CFU crosslinking agent

CNO purchased from Aldrich (USA).

COP Mandatory

COMPONENT C2

RN 78-67-1

CNM azobisisobutyronitrile

CCN Propanenitrile, 2,2'-(1,2-diazenediyl)bis[2-methyl- (ACI)

CFU initiator

CNO purchased from Aldrich (USA).

COP Mandatory

COMPONENT C4

RN 9003-39-8

CNM poly vinylpyrrolidone

CCN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI, ACI)

CAM 15 wt %

CNO purchased from Daejung (Korea).

COP Mandatory

COMPONENT C5

RN 868-77-9

CNM 2 hydroxyethyl methacrylate

CCN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester (9CI, ACI)

CNO purchased from Aldrich
 COP Mandatory

PNC author
 PNV poly-hydroxypropyl methylcellulose-vinylpyrrolidone hydrogel contact lense

PRODUCT PA1
 PUP drug delivery system
 PF Desc: hydrogel
 Desc: contact lens

TGR delivers
 TGT drug

TGR treats
 TGT eye disease

PNTE poly-hydroxypropyl methylcellulose-vinylpyrrolidone hydrogel contact lense prepared by adding crosslinking agent (EGDMA) and initiator (AIBN) to HEMA in a vial with stirring for 30 min. 80 µL of the solutions mixed with poly vinylpyrrolidone, then filled onto each plastic molds. polymerization was carried out by heating in an oven at 100 °C for 4 h, followed by washing with deionized water to remove the non-copolymerized. optical density of hydrogel contact lenses measured at 290 nm wavelength (UV-spectrophotometer, mega array, Scinco, Korea) was converted to the mass unit of the drug using a calibration curve of HPMC ($y = 20.22 x - 0.0094$). drug storage of contact lenses was performed by immersing a completely dried contact lens in 1% HPMC for 3 h. In pH change condition, the contact lenses were immersed in a 24 well plate containing PBS (0.2 mL) at the pH 5.80, 6.45, 7.20, and 8.03 for 12 h. In alternative pH condition, HEMA 100 wt %, HEMA-VP 10 wt % and HEMANIPAAm 10 wt % were immersed in a 24 well plate containing solutions (0.2 mL) of pH 5.80 and solutions of pH 8.03. immersing was carried out alternately 4 times at intervals of 30 min.

Sample Record 5

=> d bib

L3 ANSWER 1 OF 1 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:281993 CASFORMULTNS
 CPAN 2018:116915
 DN 168:380829
 ED 22 Sep 2019
 UP 13 Nov 2019
 TI pH sensitive soft contact lens for selective drug-delivery
 AU Kim, Guenhei; Kim, Hyeok Jung; Noh, Hyeran
 JT Macromolecular Research
 DT Journal
 FN Form 4
 FD Poly-Hydroxypropyl Methylcellulose-Vinylpyrrolidone Hydrogel Contact Lense: Drug Delivery System

GRPS G3; G5
 GRPC 2
 CMPC 5
 TGTC 2

Sample Record 6

L4 ANSWER 1 OF 1 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2019:239681 CASFORMULTNS
ED 28 Oct 2019
UP 11 Dec 2019
ATTR DailyMed® is produced by the National Library of Medicine. DailyMed is a registered trademark of the U.S.National Library of Medicine

DT Insert
FN Form 1
FD Penicillin V Potassium Tablet; Film Coated: Antibacterial Agent
GRPS G1-G9
GRPC 9
CMPC 9
TGTC 19

In North America
CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.

CAS Customer Center:
Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)
Fax: 614-447-3751
Email: help@cas.org
Internet: www.cas.org

In Europe
FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax: +49-7247-808-259
Email: helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan
JAICI (Japan Association for
International Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
Fax: +81-3-5978-3600
Email: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp